Literature DB >> 21801705

The complex relationship between human herpesvirus 6 and acute graft-versus-host disease.

Claire Pichereau1, Kristell Desseaux, Anne Janin, Catherine Scieux, Régis Peffault de Latour, Aliénor Xhaard, Marie Robin, Patricia Ribaud, Félix Agbalika, Sylvie Chevret, Gérard Socié.   

Abstract

The most frequent manifestation of human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) is febrile rash, raising the question of its relationship with graft-versus-host disease (GVHD). In this retrospective analysis of 365 patients who underwent allogeneic HSCT, HHV-6 reactivation was significantly associated with cord blood transplantation (hazard ratio [HR], 3.20; P < .0001) and the use of unrelated donors (HR, 2.02; P = .008). On multivariate analysis, previous GVHD was a predictive factor for HHV-6 reactivation (HR, 1.80; P = .01), and previous HHV-6 reactivation was a predictive factor for acute GVHD (HR, 1.66; P = .03). Nineteen patients with no pathological evidence of GVHD later developed severe clinical GVHD (grade III-IV), suggesting the role of HHV-6 as a trigger for severe GVHD. Furthermore, 17 patients without histopathological GVHD demonstrated a significant lymphoid infiltrate suggesting "pure" HHV-6-related manifestations, and these patients could have been spared steroid therapy.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21801705     DOI: 10.1016/j.bbmt.2011.07.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality.

Authors:  Lena E Winestone; Rajesh Punn; John S Tamaresis; Julia Buckingham; Benjamin A Pinsky; Jesse J Waggoner; Sandhya Kharbanda
Journal:  Pediatr Transplant       Date:  2017-11-27

2.  First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Xiaofeng Zhou; David N O'Dwyer; Meng Xia; Holly K Miller; Paul R Chan; Kelsey Trulik; Mathew M Chadwick; Timothy C Hoffman; Camille Bulte; Kevin Sekerak; Carol A Wilke; Swapneel J Patel; Wayne M Yokoyama; Susan Murray; Gregory A Yanik; Bethany B Moore
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

3.  Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT.

Authors:  Joshua A Hill; W Garrett Nichols; Francisco M Marty; Genovefa A Papanicolaou; Thomas M Brundage; Randall Lanier; Danielle M Zerr; Michael J Boeckh
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

4.  The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease.

Authors:  Jérôme Legoff; Matthieu Resche-Rigon; Jerome Bouquet; Marie Robin; Samia N Naccache; Séverine Mercier-Delarue; Scot Federman; Erik Samayoa; Clotilde Rousseau; Prescillia Piron; Nathalie Kapel; François Simon; Gérard Socié; Charles Y Chiu
Journal:  Nat Med       Date:  2017-07-31       Impact factor: 53.440

5.  Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation.

Authors:  Hiroyuki Muranushi; Junya Kanda; Yasuyuki Arai; Takero Shindo; Masakatsu Hishizawa; Takashi Yamamoto; Tadakazu Kondo; Kohei Yamashita; Kazuo Matsubara; Akifumi Takaori-Kondo
Journal:  Br J Clin Pharmacol       Date:  2020-05-30       Impact factor: 4.335

6.  Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation.

Authors:  T W H Flinsenberg; L Spel; M Jansen; D Koning; C de Haar; M Plantinga; R Scholman; M M van Loenen; S Nierkens; L Boon; D van Baarle; M H M Heemskerk; J J Boelens; M Boes
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

7.  Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect.

Authors:  Armin Rashidi; Maryam Ebadi; Bassil Said; Qing Cao; Ryan Shanley; Julie Curtsinger; Nelli Bejanyan; Erica D Warlick; Jaime S Green; Claudio G Brunstein; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Am J Hematol       Date:  2018-05-14       Impact factor: 10.047

8.  Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.

Authors:  Christopher C Dvorak; Amel Hassan; Mary A Slatter; Manfred Hönig; Arjan C Lankester; Rebecca H Buckley; Michael A Pulsipher; Jeffrey H Davis; Tayfun Güngör; Melissa Gabriel; Jacob H Bleesing; Nancy Bunin; Petr Sedlacek; James A Connelly; David F Crawford; Luigi D Notarangelo; Sung-Yun Pai; Jake Hassid; Paul Veys; Andrew R Gennery; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2014-08-07       Impact factor: 10.793

Review 9.  Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.

Authors:  Joshua A Hill; Danielle M Zerr
Journal:  Curr Opin Virol       Date:  2014-10-04       Impact factor: 7.090

10.  Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.

Authors:  Lorenzo Dagna; Joshua C Pritchett; Paolo Lusso
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.